NCT03560960 · Early Phase 1 · ACTIVE NOT RECRUITING
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
This study is testing whether a single injection of pramlintide, a diabetes drug already approved by the FDA, can power a blood test for early Alzheimer's. Researchers compare blood amyloid levels before and shortly after the shot. The goal is to see if the rise tracks amyloid in the brain. It is an early Phase 1 study, not a treatment.
You may qualify if
- Current research subjects at the BU , Memory Center VA Boston Healthcare, or Indiana University Alzheimer Disease Center
- A consensus diagnosis of probable Alzheimer's Disease (AD), amnestic mild cognitive impairment (MCI), or control
- BMI of 20-35
- Probable AD subjects must be confirmed for positive AD pathology in the central nervous center (CNS0
- Probable AD subjects must have a designated research proxy signed before they became demented.
You're excluded if
- Diabetes mellitus
- Gastroparesis
- Use of insulin, pramlintide, other injectable anti-hyperglycemic agents, such as glucagon like peptide-1 (GLP-1), or oral anti-diabetic products
- Unexplained hypoglycemia (glucose ≤ 60 mg/dL) or hyperglycemia (glucose ≥ 126 mg/dL) pre-injection
- History of stroke
- Seizures or use of anti-seizure medications
- History of brain injury and loss of consciousness
- Diagnosed cerebral amyloid angiopathy (CAA)
- Infection within 1 month
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-28